Methods of axillary staging How quick?

Size: px
Start display at page:

Download "Methods of axillary staging How quick?"

Transcription

1 Methods of axillary staging How quick? One step nucleic acid amplification (OSNA) for the sentinel node YLJ Vissers, surgical oncologist Atrium-Orbis Medical Center, Heerlen-Sittard

2 no conflict of interest

3 Traditional sentinel node analysis sliced for microscopic analysis Procedure takes 2 days Delays diagnosis No intra-operative analysis Remaining material is not analyzed False negatives No standardisation Inter-observer variation

4 patient s requests Reduction of waiting time for diagnoses Reduction of the number of recalls for second surgical interventions

5 Quick tests sentinel node sensivity 63% sensivity 73% Liu LC, Lang JE, Lu Y, et al. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients. Cancer. 2011;117:250 8.

6 Molecular analysis Measures amount of CK19 mrna Result as (negative) (micro) (macro) 40 minutes for definitive diagnosis

7 standardisation speed complete node analysed

8

9 Comments Not all tumours contain CK19 test beforehand Loss histology keep central slice More micrometastases detected Recklessly performed ALND s with every positive result prior review axillary treatment in pre-operative MDT

10 Users

11 Atrium-Orbis experience Pilot patients 65 lymph nodes 65 OSNA samples Result as (-) (+) (++) by courtery of H.Plasschaert, 2013

12 Results pilot Tissue allocation bias OSNA by courtery of H.Plasschaert, 2013

13 Business case

14 Indication pre-operatively type of surgery CK19 present vascular invasion BR grade tumour size Nortier JWR, Smorenburg CH, Van Dalen T, Van der Sangen MJC. Compendium behandeling van het mammacarcinoom, 2015

15 during surgery

16 Results 12 mastectomy 27 breast conserving 6 tissue expander 1 after NAC 2 macro 2 micro 7 micro 3 macro 2 ALND 2 ALND

17 10 minutes 15 minutes minutes 64 minutes

18 post-operatively 0 recalls 0 secondary ALND 5 adjuvant axillary radiotherapy 6 no adjuvant axillary treatment

19 Patient opinions Er is niets erger dan wachten op de uitslag. De eerste keer moest ik een week wachten. De spanning is ondraaglijk. Nachten lang wakker liggen. Dat was vreselijk. Ik ben echt blij met de nieuwe techniek. Het is een groot verschil met mijn eerdere ervaring. Het levert veel minder spanning op. Toen ik bijkwam uit de narcose wist ik direct wat de uitslag was. Niet meer wachten en één spanningspiek minder. Dat is voor mij het grootste pluspunt van de nieuwe werkwijze.

20 Summary Atrium-Orbis experience Intra-operative results within reasonable time frame No recalls in postoperative MDT Advantages mainly in mastectomy, direct reconstructions Patients relieved

21

22 Future?

23 Discarded if sentinel procedure or ALND becomes abandoned? Future tool for predicting which patients benefit from ALND?

24 Conclusion One step nucleic acid amplification (OSNA) for the sentinel node Reliable, quick method for sentinel node analysis Reduces need for secondary surgery direct reconstruction with prosthesis mastectomy Reduces waiting time for definite diagnosis May have future implication as prediction model for extensive nodal metastasis

25 dept.surgery J van Bastelaar L van Driel E van Haaren C Heymans F Jorna C Scheeren Acknowledgements dept.plastic surgery D Booi M Meesters T vmulken dept.pathology S Corvers K Machielsen P Sastrowijoto R Smeets W Vos H Plasschaert (currently Antwerp) MAASTRO dept.oncology F Erdkamp R vkampen F Peters M Portz dept.radiology A Muller M Osinga H vdpol

26 Molecular analysis upstaged 13% (52 of 394) node-negative patients. At mean follow-up of 7 years, these patients had a significantly lower distant recurrence-free survival Patients with N0(mol+) disease are 3.4 times more likely to experience relapse than PCRnegative patients (P =.001) Verbanac K.M., Min C.J., Mannie A.E., et al: Long-term follow-up study of a prospective multicenter sentinel node trial: molecular detection of breast cancer sentinel node metastases. Ann Surg Oncol 2010; 17(Suppl 3):

27

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT

PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT PROTOCOL SENTINEL NODE BIOPSY (NON OPERATIVE) BREAST CANCER - PATHOLOGY ASSESSMENT Author: Dr Sally Ann Hales On behalf of the Breast and pathology CNGs Written: March 2005 Reviewed by CNG: June 2009 &

More information

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD

Sentinel Node Biopsy. Is There Any Role for Axillary Dissection? JCCNB Nov 20, Stephen B. Edge, MD Sentinel Node Biopsy Is There Any Role for Axillary Dissection? JCCNB Nov 20, 2010 Tokyo, Japan Stephen B. Edge, MD Roswell Park Cancer Institute University at Buffalo Buffalo, NY USA SNB with Clinically

More information

Recent Advances in Breast Cancer Treatment

Recent Advances in Breast Cancer Treatment Recent Advances in Breast Cancer Treatment Pornchai O-charoenrat MD, PhD, FRCST, FICS Professor Chief, Division of Head-Neck & Breast Surgery Department of Surgery, Siriraj Hospital, THAILAND Recent Advances

More information

RD-100i OSNA the new generation of sentinel lymph node analysis in breast cancer

RD-100i OSNA the new generation of sentinel lymph node analysis in breast cancer RD-1i OSNA the new generation of sentinel lymph node analysis in breast cancer RD-1i OSNA the new generation of sentinel lymph node analysis in breast cancer Sentinel node biopsy has rapidly emerged as

More information

Can OSNA CK19 copy number predict nodal status when axillary dissection is not performed?

Can OSNA CK19 copy number predict nodal status when axillary dissection is not performed? Can OSNA CK19 copy number predict nodal status when axillary dissection is not performed? The OSNA CK19 mrna copy number in the SLN was the only inde pendent predictor of 4 LN having metastases. Ohi et

More information

NICE diagnostics guidance on intraoperative tests (RD 100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer

NICE diagnostics guidance on intraoperative tests (RD 100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer NICE diagnostics guidance on intraoperative tests (RD 100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer NICE provided the content for this booklet which is

More information

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer

Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer - Official Statement - Position Statement on Management of the Axilla in Patients with Invasive Breast Cancer Sentinel lymph node (SLN) biopsy has replaced axillary lymph node dissection (ALND) for the

More information

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015

Breast Surgery When Less is More and More is Less. E MacIntosh, MD June 6, 2015 Breast Surgery When Less is More and More is Less E MacIntosh, MD June 6, 2015 Presenter Disclosure Faculty: E. MacIntosh Relationships with commercial interests: None Mitigating Potential Bias Not applicable

More information

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction

Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version History Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version Summary of change Date Issued 2.0 Endorsed by the Governance Committee 20.02.08 2.1 Circulated

More information

RD-100i OSNA the new generation of sentinel lymph node analysis in breast cancer

RD-100i OSNA the new generation of sentinel lymph node analysis in breast cancer RD-1i OSNA the new generation of sentinel lymph node analysis in breast cancer www.sysmex-europe.com RD-1i OSNA the new generation of sentinel lymph node analysis in breast cancer Sentinel node biopsy

More information

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM

Ines Buccimazza 16 TH UP CONTROVERSIES AND PROBLEMS IN SURGERY SYMPOSIUM BILATERAL MASTECTOMY IS NOT ROUTINELY JUSTIFIED IN PATIENTS WITH BILATERAL AXILLARY LYMPHADENOPATHY AND ONLY ONE DETECTABLE PRIMARY BREAST CANCER LESION SURGERY SYMPOSIUM Ines Buccimazza Breast Unit Department

More information

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy

Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Clinical Outcome of Reconstruction With Tissue Expanders for Patients With Breast Cancer and Mastectomy Mitsui Memorial Hospital Department of Breast and Endocine surgery Daisuke Ota No financial support

More information

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes

16/09/2015. ACOSOG Z011 changing practice. Presentation outline. Nodal mets #1 prognostic tool. Less surgery no change in oncologic outcomes ACOSOG Z011 changing practice The end of axillary US/FNA? Preoperative staging of the axilla in the era of Z011 Adena S Scheer MD MSc FRCSC Surgical Oncologist, St. Michael s Hospital Assistant Professor,

More information

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection

The Role of Sentinel Lymph Node Biopsy and Axillary Dissection The Role of Sentinel Lymph Node Biopsy and Axillary Dissection Henry Mark Kuerer, MD, PhD, FACS Department of Surgical Oncology University of Texas MD Anderson Cancer Center SLN Biopsy Revolutionized surgical

More information

ALND. Dr. MJ Vrancken

ALND. Dr. MJ Vrancken ALND Dr. MJ Vrancken ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice opera8on; dorsal approach 2 ALND in primary surgery se1ng Axillary lymph node dissec8on (ALND) Very nice

More information

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration

Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed

More information

Sentinel Lymph Node Biopsy for Breast Cancer

Sentinel Lymph Node Biopsy for Breast Cancer Sentinel Lymph Node Biopsy for Breast Cancer Registrar Tutorial Adam Cichowitz Surgical Registrar The Royal Melbourne Hospital Sentinel Lymph Node Biopsy Axillary LN status important prognostic factor

More information

Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy

Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy The London Cancer Alliance West and South Sentinel Lymph Node Biopsy Should be Performed BEFORE Neoadjuvant Chemotherapy Dimitri J Hadjiminas, MD, MPhil, FRCS (Consultant Breast & Endocrine Surgeon Imperial

More information

THE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital

THE SURGEON S ROLE: THE AXILLA. Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital THE SURGEON S ROLE: THE AXILLA Owen A Ung University of Queensland Royal Brisbane and Women s Hospital Wesley and St Andrews Hospital What are the concerns with treatment to the axilla Not necessary for

More information

Results of the ACOSOG Z0011 Trial

Results of the ACOSOG Z0011 Trial DCIS and Early Breast Cancer Symposium JUNE 15-17 2012 CAPPADOCIA Results of the ACOSOG Z0011 Trial Kelly K. Hunt, M.D. Professor of Surgery Axillary Node Dissection Staging, Regional control, Survival

More information

Diagnostics guidance Published: 7 August 2013 nice.org.uk/guidance/dg8

Diagnostics guidance Published: 7 August 2013 nice.org.uk/guidance/dg8 Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast cancer Diagnostics guidance Published: 7 August 2013 nice.org.uk/guidance/dg8 NICE 2018.

More information

Ultrasound or FNA for Predicting Node Positive in Breast Cancer

Ultrasound or FNA for Predicting Node Positive in Breast Cancer Ultrasound or FNA for Predicting Node Positive in Breast Cancer Chiun Sheng Huang, MD, PhD, MPH Professor and Chairman Department of Surgery Director of Breast Care Center National Taiwan University Hospital

More information

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda

Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies. Agenda Head & Neck Squamous Carcinoma: Artifacts, Challenges, and Controversies Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University

More information

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery

Surgical Advances in the Treatment of Breast Cancer. Laura Kruper, MD, MSCE Chief, Breast Surgery Surgical Advances in the Treatment of Breast Cancer Laura Kruper, MD, MSCE Chief, Breast Surgery Nothing to disclose DISCLOSURE LESS IS MORE Radiation Lymph nodes Reconstruction Less is More! Radiation

More information

Updates on management of the axilla in breast cancer the surgical point of view

Updates on management of the axilla in breast cancer the surgical point of view Updates on management of the axilla in breast cancer the surgical point of view Edwige Bourstyn Centre des maladies du sein Hôpital Saint Louis Paris Sentinel lymph node biopsy (SLNB) is the standard of

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Diagnostics Assessment Programme

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Diagnostics Assessment Programme NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Diagnostics Assessment Programme Intraoperative tests (RD-100i OSNA system and Metasin test) for detecting sentinel lymph node metastases in breast

More information

Should we still be performing IHC on all sentinel nodes?

Should we still be performing IHC on all sentinel nodes? Miami Breast Cancer Conference 31 st Annual Conference March 8, 2014 Should we still be performing IHC on all sentinel nodes? Donald L. Weaver, MD Professor of Pathology University of Vermont USA Miami

More information

Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options

Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate

More information

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease?

Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Is Complete Axillary Dissection Needed Following Mastectomy and Sentinel Node Biopsy for N1 disease? Mylin A. Torres, MD Director, Glenn Family Breast Center Louis and Rand Glenn Family Chair in Breast

More information

Maria João Cardoso, MD, PhD

Maria João Cardoso, MD, PhD Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No

More information

National Breast Cancer Audit next steps. Martin Lee

National Breast Cancer Audit next steps. Martin Lee National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast

More information

I. Veys, S. Majjaj, R. Salgado, D. Noterman, J. C. Schobbens, F. Manouach, P. Bourgeois, J. M. Nogaret, D. Larsimont, V. Durbecq

I. Veys, S. Majjaj, R. Salgado, D. Noterman, J. C. Schobbens, F. Manouach, P. Bourgeois, J. M. Nogaret, D. Larsimont, V. Durbecq Evaluation of the histological size of the sentinel lymph node metastases using RT PCR assay: a rapid tool to estimate the risk of non-sentinel lymph node invasion in patients with breast cancer I. Veys,

More information

Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial

Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial DISCIPLINA DE MASTOLOGIA ESCOLA PAULISTA DE MEDICINA UNIVERSIDADE FEDERAL DE SÃO PAULO Management of the Axilla at Initial Surgery Manejo da Axila em Cirurgia Inicial Disciplina de Mastologia Prof. Dr.

More information

NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham. Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence

NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham. Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence 1 Interactive Workshop Session Professor Kieran Horgan Workshop

More information

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective :$;7)#*8'-87*4BCD'E7)F'31$4.$&'G$H'E7)F&'GE'>??ID >?,"'@4,$)4*,#74*8'!74/)$++'74',"$'A.,.)$'7%'()$*+,'!*42$)!7)74*67&'!3 6 August 2011 Implications of ACOSOG Z11 for Clinical

More information

Point of view of the surgeons

Point of view of the surgeons NEOADJUVANT THERAPY: WHEN AND HOW? Point of view of the surgeons Dr. M. Danaei Head of Breast Unit Marienhospital Aachen Germany 2 3 Neoadjuvant therapy and overall survival: 4 Neoadjuvant therapy: concept

More information

Savitri Krishnamurthy, MD 1

Savitri Krishnamurthy, MD 1 EVOLVING TRENDS IN PATHOLOGIC EVALUATION OF AXILLARY LYMPH NODES IN BREAST CANCER Savitri Krishnamurthy, M.D. Professor Department of Pathology University of Texas M. D. Anderson Cancer Center AXILLARY

More information

DOES NEOADJUVANT Rx REALLY DOWN STAGE BR CA? DR KHANYILE DEPARTMENT OF MEDICAL ONCOLOGY, University of Pretoria

DOES NEOADJUVANT Rx REALLY DOWN STAGE BR CA? DR KHANYILE DEPARTMENT OF MEDICAL ONCOLOGY, University of Pretoria DOES NEOADJUVANT Rx REALLY DOWN STAGE BR CA? DR KHANYILE DEPARTMENT OF MEDICAL ONCOLOGY, University of Pretoria BREAST CA STAGING TNM STAGING: - T x N - x - 0-0 - is - 1-1(1mic/1a/1b/1c) - 2(a/b) - 2-3(a/b/c)

More information

Radiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015

Radiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015 Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,

More information

Neoadjuvant Treatment of. of Radiotherapy

Neoadjuvant Treatment of. of Radiotherapy Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect

More information

Treating today s patients with tomorrow s solutions

Treating today s patients with tomorrow s solutions Treating today s patients with tomorrow s solutions 1st conference supported by: European Multidisciplinary Breast Cancer Collaborative (EMBCC) February 5-6, 2016 Maison des oceans Paris EMBCC board members

More information

Table of contents. Page 2 of 40

Table of contents. Page 2 of 40 Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the

More information

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer.

Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Retrospective analysis to determine the use of tissue genomic analysis to predict the risk of recurrence in early stage invasive breast cancer. Goal of the study: 1.To assess whether patients at Truman

More information

At many centers in the United States and worldwide,

At many centers in the United States and worldwide, ORIGINAL ARTICLES A Declining Rate of Completion Axillary Dissection in Sentinel Lymph Node-positive Breast Cancer Patients Is Associated With the Use of a Multivariate Nomogram Julia Park, MS, Jane V.

More information

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center

Targeting Surgery for Known Axillary Disease. Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Targeting Surgery for Known Axillary Disease Abigail Caudle, MD Henry Kuerer, MD PhD Dept. Surgical Oncology MD Anderson Cancer Center Nodal Ultrasound at Diagnosis Whole breast and draining lymphatic

More information

Breast Cancer Staging

Breast Cancer Staging Breast Cancer Staging Symposium on Best Practice in Recording Cancer Stage Royal College of Pathologists 10 June 2011 Dr Gill Lawrence, Director Tel: 0121 415 8129 Fax: 0121 414 7712 Email: gill.lawrence@wmciu.nhs.uk

More information

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest

Debate Axillary dissection - con. Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Debate Axillary dissection - con Prof. Dr. Rodica Anghel Institute of Oncology Bucharest Summer School of Oncology, third edition Updated Oncology 2015: State of the Art News & Challenging Topics Bucharest,

More information

Evaluating the Z011 study and how local-regional therapy for early breast cancer may change

Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Evaluating the Z011 study and how local-regional therapy for early breast cancer may change Karen Hoffman, M.D., M.H.Sc., M.P.H. Dept of Radiation Oncology The University of Texas MD Anderson Cancer Center

More information

San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective. Disclosures

San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective. Disclosures San Antonio Breast Cancer Symposium 2010: Highlights from a Surgical Perspective January 18, 2011 Association of Northern California Oncologists Steven Chen, MD, MBA Chief, Breast Surgery University of

More information

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective

Implications of ACOSOG Z11 for Clinical Practice: Surgical Perspective Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA 6 August 2011 Implications of ACOSOG Z11 for Clinical

More information

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:

ANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to: 1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications

More information

ORIGINAL ARTICLE BREAST ONCOLOGY. Ann Surg Oncol (2010) 17: DOI /s x

ORIGINAL ARTICLE BREAST ONCOLOGY. Ann Surg Oncol (2010) 17: DOI /s x Ann Surg Oncol (2010) 17:2690 2695 DOI 10.1245/s10434-010-1052-x ORIGINAL ARTICLE BREAST ONCOLOGY Discordance of Intraoperative Frozen Section Analysis with Definitive Histology of Sentinel Lymph Nodes

More information

Pathology Report Patient Companion Guide

Pathology Report Patient Companion Guide Pathology Report Patient Companion Guide Breast Cancer - Understanding Your Pathology Report Pathology Reports can be overwhelming. They contain scientific terms that are unfamiliar and might be a bit

More information

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator

More information

Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection

Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection 456 Use of the dye guided sentinel lymph node biopsy method alone for breast cancer metastasis to avoid unnecessary axillary lymph node dissection TOMOKO TAKAMARU 1, GORO KUTOMI 1, FUKINO SATOMI 1, HIROAKI

More information

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology

Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant

More information

Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift. Edi Brogi MD PhD Attending Pathologist Director of Breast Pathology

Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift. Edi Brogi MD PhD Attending Pathologist Director of Breast Pathology Sentinel Lymph Nodes for Breast Carcinoma: A Paradigm Shift Edi Brogi MD PhD Attending Pathologist Director of Breast Pathology Sentinel Lymph Nodes 2014 AJCC 2010 staging Micrometastases Occult metastases

More information

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact

Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most

More information

INTRAOPERATIVE CYTOLOGY: PAST, PRESENT, AND FUTURE

INTRAOPERATIVE CYTOLOGY: PAST, PRESENT, AND FUTURE INTRAOPERATIVE CYTOLOGY: PAST, PRESENT, AND FUTURE Steven G. Silverberg, M.D., FRCPath Department of Pathology University of Maryland, Baltimore Presentation Bullet Points Intraoperative consultations

More information

The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon Cancer Patients

The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon Cancer Patients Ann Surg Oncol (2014) 21:3924 3930 DOI 10.1245/s10434-014-3820-5 ORIGINAL ARTICLE COLORECTAL CANCER The Diagnostic Value of One-Step Nucleic acid Amplification (OSNA) for Sentinel Lymph Nodes in Colon

More information

Evolution of Regional Nodal Management of Breast Cancer

Evolution of Regional Nodal Management of Breast Cancer Evolution of Regional Nodal Management of Breast Cancer Bruce G. Haffty, MD Director (Interim) Rutgers Cancer Institute of New Jersey Professor and Chair Department of Radiation Oncology Rutgers, The State

More information

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015

Advances in Breast Surgery. Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Advances in Breast Surgery Catherine Campo, D.O. Breast Surgeon Meridian Health System April 17, 2015 Objectives Understand the surgical treatment of breast cancer Be able to determine when a lumpectomy

More information

Surgery for Breast Cancer

Surgery for Breast Cancer Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85

More information

Evaluation of the Axilla Post Z-0011 Trial New Paradigm

Evaluation of the Axilla Post Z-0011 Trial New Paradigm Evaluation of the Axilla Post Z-0011 Trial New Paradigm Belinda Curpen, MD, FRCPC; Tetyana Dushenkovska; Mia Skarpathiotakis MD, FRCPC; Carrie Betel, MD, FRCPC; Kalesha Hack, MD, FRCPC; Lara Richmond,

More information

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged:

Relevance. Axillary Node Recurrence. Purpose. Case Presentation: Is axillary staging required? Two trends have emerged: Axillary Node Recurrence N.L. Davis Associate Professor of Surgery, UBC Head of Surgical Oncology, BCCA Relevance In an attempt to minimize long term complications and to maximize cancer control, the management

More information

Attending Physician Statement- Cancer or Carcinoma in-situ

Attending Physician Statement- Cancer or Carcinoma in-situ Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Cancer or Carcinoma in-situ.

More information

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016

Breast Cancer: Management of the Axilla in Greg McKinnon MD FRCSC SON Vancouver Oct 2016 Breast Cancer: Management of the Axilla in 2016 Greg McKinnon MD FRCSC SON Vancouver Oct 2016 No Disclosures Principle #1 There is no point talking about surgical therapy in isolation. From a patient

More information

Feasibility Of Day Surgery In Patients With Breast

Feasibility Of Day Surgery In Patients With Breast 583201SJS0010.1177/1457496915583201K. Ojala, J. H. Vironen, K. Mattila, A. M. Eklund, M. H. K. Leidenius, T. J. MeretojaScandinavian Journal of Surgery research-article2015 ORIGINAL ARTICLE Scandinavian

More information

Evolution of Breast Surgery

Evolution of Breast Surgery Evolution of Breast Surgery Natasha Rueth MD Surgical Oncologist Piper Breast Center and Alina Health Surgical Specialists Minneapolis, MN Definitions Radical Mastectomy: Removal of breast, chest muscles,

More information

ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data

ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data ESGO-ESTRO-ESP Cervical Cancer Clinical Practice Guidelines Management of early stages: algorithms focusing on the histological data David Cibula Gynecologic Oncology Centre General University Hospital

More information

Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh

Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh Early Rectal Cancer Surgical options Organ Preservation? Chinna Reddy Colorectal Surgeon Western General, Edinburgh What is Early rectal cancer? pt1t2n0m0 Predictors for LN involvement Size Depth Intramural

More information

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit.

Page 1. AHN-JHU Breast Cancer Symposium. Novel Local Regional Clinical Trials. Background. Neoadjuvant Chemotherapy Benefit. AHN-JHU Breast Cancer Symposium Novel Local Regional Clinical Trials March 22, 2019 Thomas B. Julian, MD, FACS Associate Medical Director, Cancer Program Development, ANH Cancer Institute Background In

More information

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery

Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Breast Cancer Res Treat (2016) 160:387 391 DOI 10.1007/s10549-016-4017-3 EDITORIAL Outcomes of patients with inflammatory breast cancer treated by breast-conserving surgery Monika Brzezinska 1 Linda J.

More information

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer

The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer The Challenge of Individualizing Loco-Regional Treatments for Patients with Localized Breast Cancer Le défi des traitements locorégionaux individualisés pour les patientes présentant un cancer du sein

More information

Causation Issues. Delay in Diagnosis of Cancer Cases. Prof Pat Price Imperial College London

Causation Issues. Delay in Diagnosis of Cancer Cases. Prof Pat Price Imperial College London Causation Issues Delay in Diagnosis of Cancer Cases Prof Pat Price Imperial College London office@patprice.co.uk www.patprice.co.uk Faculty of Advocates Annual conference 18 th June 2018 EVIDENCE BASED

More information

Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study

Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study [ABS-0078] GBCC 2018 Feasibility of Preoperative Axillary Lymph Node Marking with a Clip in Breast Cancer Patients before Neoadjuvant Chemotherapy: A Preliminary Study Eun Young Kim 1, Kwan Ho Lee 1, Yong

More information

Intervention(s) Results primary outcome Results secondary and other outcomes

Intervention(s) Results primary outcome Results secondary and other outcomes Uitgangsvraag 4: evidence tables Welke nieuwe vormen van risicoprofilering zijn - in tegenstelling tot de traditionele prognostische factoren als tumorgrootte, lymfklierstatus en tumorgradering - van invloed

More information

Radiotherapy after neo-adjuvant chemotherapy

Radiotherapy after neo-adjuvant chemotherapy Radiotherapy after neo-adjuvant chemotherapy Lustrumcongres Moeilijke Mamma s 31 januari 2014 dr Paula Elkhuizen Radiotherapeut-oncoloog Indications for neoadjuvant chemotherapy (NAC) - Patients with inflammatory

More information

Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care

Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care 4 th International Congress of Breast Role of Cancer Registries and Data Banking in Quality Control of Breast Cancer Care Adri C. Voogd, PhD, epidemiologist Department of Epidemiology, Maastricht University

More information

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery

Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing Breast Conserving Surgery Ann Surg Oncol (2015) 22:1128 1132 DOI 10.1245/s10434-014-4090-y ORIGINAL ARTICLE BREAST ONCOLOGY Applicability of the ACOSOG Z0011 Criteria in Women with High-Risk Node-Positive Breast Cancer Undergoing

More information

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation

Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer

More information

Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience

Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience NCIN Annual Conference, National Motorcycle Museum June 2008 Dr Gill Lawrence West Midlands Cancer

More information

Follow-up Care of Breast Cancer Patients

Follow-up Care of Breast Cancer Patients Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures

More information

Breast Cancer Breast Managed Clinical Network

Breast Cancer Breast Managed Clinical Network Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive

More information

Financial Disclosure. Learning Objectives. None. To understand the clinical applicability of the NCDB Breast Cancer PUF

Financial Disclosure. Learning Objectives. None. To understand the clinical applicability of the NCDB Breast Cancer PUF Preoperative Prediction of Node Negative Disease After Neoadjuvant Chemotherapy in Patients Presenting with Node Negative or Node Positive Breast Cancer Brittany L Murphy MD, Tanya Hoskin MS, Courtney

More information

Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ

Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ Incidence and prediction of invasive disease and nodal metastasis in preoperatively diagnosed ductal carcinoma in situ Tomo Osako, 1,2 Takuji Iwase, 3 Masaru Ushijima, 4 Rie Horii, 2 Yasuyoshi Fukami,

More information

The Premier Nodal Platform-Sentinel Lymph Node

The Premier Nodal Platform-Sentinel Lymph Node Review Article imedpub Journals www.imedpub.com The Premier Nodal Platform-Sentinel Lymph Node Anubha Bajaj* Department of Pathology, Punjab University, Chandigarh, India Abstract Sentinel Lymph Node (SLN)

More information

NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE

NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY

More information

Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care

Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care Measure #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY DESCRIPTION: The percentage

More information

Oncoplastic breast surgery in a Danish perspective II: Reconstructive strategy in oncoplastic breast surgery

Oncoplastic breast surgery in a Danish perspective II: Reconstructive strategy in oncoplastic breast surgery Oncoplastic breast surgery in a Danish perspective II: Reconstructive strategy in oncoplastic breast surgery Michael Rose, MD Department of Surgery and Plastic Surgery, Hospital of Southwest Jutland, Denmark

More information

LIPOFILLING AND ONCOPLASTIC BREAST SURGERY : oncologic safety

LIPOFILLING AND ONCOPLASTIC BREAST SURGERY : oncologic safety LIPOFILLING AND ONCOPLASTIC BREAST SURGERY : oncologic safety JY Petit IEO Milan December 13-15, 2012 29 th Annual New York Controversies, Problems & Techniques in Surgery SYMPOSIUM COURSE DIRECTORS Robert

More information

M D..,., M. M P.. P H., H, F. F A.. A C..S..

M D..,., M. M P.. P H., H, F. F A.. A C..S.. Implications of NSABP B-32 and Loco-Regional Therapy Considerations After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H, F.A.C.S. Professor of Surgery Northeastern Ohio Medical University Medical

More information

Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial)

Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial) Annals of Oncology 11: 515-519, 2000. 2000 Kluwer Academic Publishers. Printed in the Netherlands. Original article Delayed adjuvant tamoxifen: Ten-year results of a collaborative randomized controlled

More information

Loco-Regional Management After Neoadjuvant Chemotherapy

Loco-Regional Management After Neoadjuvant Chemotherapy 1 Loco-Regional Management After Neoadjuvant Chemotherapy Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor of Surgery,

More information

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy

Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Surgical Considerations in Breast Cancer treated with Neoadjuvant Therapy Rebecca Warburton MD Department of Surgery, University of British Columbia Mount Saint Joseph Hospital, Providence Health Care

More information

Recent Update in Surgery for the Management of Breast Cancer

Recent Update in Surgery for the Management of Breast Cancer Recent Update in Surgery for the Management of Breast Cancer Wonshik Han, MD, PhD Professor, Department of Surgery, Seoul National University College of Medicine Chief of Breast Care Center, Seoul National

More information

Is Sentinel Node Biopsy Practical?

Is Sentinel Node Biopsy Practical? Breast Cancer Is Sentinel Node Biopsy Practical? Benefits and Limitations JMAJ 45(10): 444 448, 2002 Shigeru IMOTO *1, Satoshi EBIHARA *2 and Noriyuki MORIYAMA *3 *1 Breast Surgery Division, National Cancer

More information

CURRENT ISSUES IN TRANSPLANT DERMATOLOGY

CURRENT ISSUES IN TRANSPLANT DERMATOLOGY CURRENT ISSUES IN TRANSPLANT DERMATOLOGY NO CONFLICTS OF INTEREST TO DISCLOSE SOLID ORGAN TRANSPLANTATION: 2015 As of April 10, 2015.. 123,319 patients waiting for an organ transplant 2,557 performed this

More information

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients

Why Do Axillary Dissection? Nodal Treatment and Survival NSABP B04. Revisiting Axillary Dissection for SN Positive Patients Memorial Sloan-Kettering Cancer Center 1275 York Avenue, New York, NY 10065 10th International Congress on the Future of Breast Cancer Coronado, CA Why Do Axillary Dissection? 6 August 2011 Implications

More information

Cervical Cancer: 2018 FIGO Staging

Cervical Cancer: 2018 FIGO Staging Cervical Cancer: 2018 FIGO Staging Jonathan S. Berek, MD, MMS Laurie Kraus Lacob Professor Stanford University School of Medicine Director, Stanford Women s Cancer Center Senior Scientific Advisor, Stanford

More information